Webinar: Latest advances in our understanding of hereditary amyloid transthyretin (hATTR) amyloidosis
This PTC Therapeutics-sponsored webinar discusses the latest advances in our understanding of hATTR amyloidosis, from proposed disease mechanisms to obtaining an accurate diagnosis
Learn about the significance of genetic mutations and manifestations of disease Understand the differences between early and late onset neuropathy phenotypes Listen to an overview of approved treatments in hATTR
This is a recording of our live webinar. This webinar recording has been chapterized to enable ease of viewing.
Register now to unlock the content
Register now to access the content on this page
If not, register below
GL-hATTR-0205 | January 2022
Close Register here to access the content on the site MED-ALL-CORP-2200029 | December 2022
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our
Privacy Statement and our Terms and Conditions do not apply.
MED-ALL-CORP-2200029 | December 2022
Close COMING SOON
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available,